Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $45.7 million.

  • Spyre Therapeutics' Non Operating Income rose 34308.58% to $45.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.9 million, marking a year-over-year increase of 31964.27%. This contributed to the annual value of -$20.7 million for FY2024, which is 7853.86% up from last year.
  • Spyre Therapeutics' Non Operating Income amounted to $45.7 million in Q3 2025, which was up 34308.58% from $5.2 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Non Operating Income registered a high of $45.7 million during Q3 2025, and its lowest value of -$57.8 million during Q2 2023.
  • Its 5-year average for Non Operating Income is -$2.4 million, with a median of -$15000.0 in 2021.
  • As far as peak fluctuations go, Spyre Therapeutics' Non Operating Income surged by 262000.0% in 2022, and later crashed by 5315321.1% in 2023.
  • Over the past 5 years, Spyre Therapeutics' Non Operating Income (Quarter) stood at -$15000.0 in 2021, then surged by 2620.0% to $378000.0 in 2022, then crashed by 4667.72% to -$17.3 million in 2023, then skyrocketed by 95.26% to -$818000.0 in 2024, then surged by 5687.41% to $45.7 million in 2025.
  • Its Non Operating Income was $45.7 million in Q3 2025, compared to $5.2 million in Q2 2025 and $8.8 million in Q1 2025.